X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA PIRAMAL ENTERPRISES AUROBINDO PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 15.6 39.7 39.4% View Chart
P/BV x 4.0 3.3 121.5% View Chart
Dividend Yield % 0.4 0.7 52.8%  

Financials

 AUROBINDO PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
PIRAMAL ENTERPRISES
Mar-17
AUROBINDO PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs8952,095 42.7%   
Low Rs6221,025 60.7%   
Sales per share (Unadj.) Rs254.6492.8 51.7%  
Earnings per share (Unadj.) Rs39.372.6 54.1%  
Cash flow per share (Unadj.) Rs46.694.7 49.2%  
Dividends per share (Unadj.) Rs2.5021.00 11.9%  
Dividend yield (eoy) %0.31.3 24.5%  
Book value per share (Unadj.) Rs160.0862.5 18.5%  
Shares outstanding (eoy) m585.88172.56 339.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.03.2 94.1%   
Avg P/E ratio x19.321.5 89.8%  
P/CF ratio (eoy) x16.316.5 98.8%  
Price / Book Value ratio x4.71.8 262.1%  
Dividend payout %6.428.9 22.0%   
Avg Mkt Cap Rs m444,390269,194 165.1%   
No. of employees `00014.04.0 348.4%   
Total wages/salary Rs m17,67817,939 98.5%   
Avg. sales/employee Rs Th10,667.821,190.3 50.3%   
Avg. wages/employee Rs Th1,264.34,470.1 28.3%   
Avg. net profit/employee Rs Th1,645.83,120.0 52.8%   
INCOME DATA
Net Sales Rs m149,15785,037 175.4%  
Other income Rs m1,1592,338 49.6%   
Total revenues Rs m150,31687,374 172.0%   
Gross profit Rs m34,34334,991 98.1%  
Depreciation Rs m4,2763,817 112.0%   
Interest Rs m66720,310 3.3%   
Profit before tax Rs m30,55813,202 231.5%   
Minority Interest Rs m501,699 3.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-100 0.0%   
Tax Rs m7,5972,281 333.0%   
Profit after tax Rs m23,01212,520 183.8%  
Gross profit margin %23.041.1 56.0%  
Effective tax rate %24.917.3 143.9%   
Net profit margin %15.414.7 104.8%  
BALANCE SHEET DATA
Current assets Rs m92,06287,590 105.1%   
Current liabilities Rs m66,223185,578 35.7%   
Net working cap to sales %17.3-115.2 -15.0%  
Current ratio x1.40.5 294.5%  
Inventory Days Days10631 341.4%  
Debtors Days Days6848 142.3%  
Net fixed assets Rs m62,919108,523 58.0%   
Share capital Rs m586345 169.8%   
"Free" reserves Rs m93,133148,481 62.7%   
Net worth Rs m93,719148,826 63.0%   
Long term debt Rs m1,814144,957 1.3%   
Total assets Rs m162,494482,394 33.7%  
Interest coverage x46.81.7 2,836.3%   
Debt to equity ratio x01.0 2.0%  
Sales to assets ratio x0.90.2 520.7%   
Return on assets %14.66.8 214.1%  
Return on equity %24.68.4 291.9%  
Return on capital %32.712.0 273.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m75,83815,001 505.6%   
Fx outflow Rs m30,2245,150 586.9%   
Net fx Rs m45,6139,851 463.0%   
CASH FLOW
From Operations Rs m32,786-100,393 -32.7%  
From Investments Rs m-17,870-24,202 73.8%  
From Financial Activity Rs m-19,153135,705 -14.1%  
Net Cashflow Rs m-4,23911,110 -38.2%  

Share Holding

Indian Promoters % 54.1 52.9 102.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 4.0 198.8%  
FIIs % 27.7 26.6 104.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 16.5 61.8%  
Shareholders   69,601 93,274 74.6%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   UNICHEM LAB  SUN PHARMA  PFIZER  FDC LTD.  SHASUN PHARMA  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Sensex Touching New Highs, Takeaways from Acquisition of HPCL and Top Stocks in Action Today(Pre-Open)

BSE Sensex is on a roll. The index touched a record high of 35,798 yesterday. Considering a span of one year, the benchmark index has delivered a 32% return.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 23, 2018 09:25 AM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS